Inactive Instrument

Bausch Health Companies Inc Stock Toronto S.E.

Equities

CA91911K1021

Pharmaceuticals

Sales 2024 * 9.38B 12.84B Sales 2025 * 9.64B 13.19B Capitalization 2.97B 4.06B
Net income 2024 * 240M 328M Net income 2025 * 389M 532M EV / Sales 2024 * 2.49 x
Net Debt 2024 * 20.44B 27.96B Net Debt 2025 * 19.09B 26.12B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
15.9 x
P/E ratio 2025 *
7.68 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.66%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 -
Director of Finance/CFO 51 22-05-23
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 08-07-31
Chairman 68 17-05-31
Director/Board Member 35 21-03-16
More insiders
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Calendar
More about the company